Objectif
With the increasing volume of genetic sequences, bioinformatics methods, data about variants and mutations, and research publications, clinical interpretation remains a complex and labour-intensive task. As a result, clinical interpretation became the costly piece of genetic testing, limiting scale, keeping turnaround time high, and driving up costs of a test. Moreover, after the geneticist’s work is done, clinicians still remain with partial, insufficient information to base their clinical decisions on.
Emedgene have developed an ICT platform for clinical interpretation of genomic data. The platform continuously scans all public resources and databases available, retrieves information from written publications using Natural Language Processing, and intelligently integrates the data into unified ontologies. It is the first artificial intelligence platform, modelled on the behaviour of sophisticated genomic interpreters, to automatically pinpoint the unique disease-causing variants and deliver results with solid evidence and reasoning, providing a clear path to clinical decisions.
Within the overall project, Emedgene plan to optimise the platforms interpretations capabilities, demonstrate and validate it in clinical environments, and fully establish the European commercialisation strategy.
Champ scientifique
- natural sciencescomputer and information sciencesartificial intelligence
- medical and health scienceshealth scienceshealth care serviceseHealth
- natural sciencescomputer and information sciencesdata sciencenatural language processing
- social scienceseconomics and businessbusiness and managementbusiness models
- natural sciencesbiological sciencesgeneticsmutation
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
6107002 TEL AVIV
Israël
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.